SU

SUSMED, Inc.

Develops digital therapeutics (DTx) and AI systems to streamline clinical development.

4263 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
中央区日本橋本町三丁目7番2号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

SUSMED, Inc. is a research and development-focused company that promotes digital medicine under the concept of "sustainable medicine." The company's business is centered on two main pillars: the development of therapeutic smartphone applications (Digital Therapeutics/DTx) for various diseases, such as its government-approved app for insomnia, and the provision of digital systems to support and streamline clinical development for pharmaceutical companies. SUSMED leverages technologies, including AI and blockchain, to enhance the efficiency of clinical trials and create new medical solutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-26 08:32
Regulatory News Service
確認書
Japanese 8.6 KB
2025-09-26 08:31
Annual Report
有価証券報告書-第10期(2024/07/01-2025/06/30)
Japanese 1.9 MB
2025-02-14 07:30
Interim Report
確認書
Japanese 8.6 KB
2025-02-14 07:30
Interim Report
半期報告書-第10期(2024/07/01-2025/06/30)
Japanese 230.1 KB
2024-09-27 08:03
Post-Annual General Meeting Information
臨時報告書
Japanese 29.8 KB
2024-09-27 08:02
Governance Information
内部統制報告書-第9期(2023/07/01-2024/06/30)
Japanese 22.5 KB
2024-09-27 08:01
Registration Form
確認書
Japanese 8.6 KB
2024-09-27 08:01
Annual Report
有価証券報告書-第9期(2023/07/01-2024/06/30)
Japanese 1.9 MB
2024-05-10 08:01
Regulatory News Service
確認書
Japanese 8.6 KB
2024-05-10 08:00
Quarterly Report
四半期報告書-第9期第3四半期(2024/01/01-2024/03/31)
Japanese 181.5 KB
2024-02-14 07:01
Report Publication Announcement
確認書
Japanese 8.6 KB
2024-02-14 07:00
Quarterly Report
四半期報告書-第9期第2四半期(2023/10/01-2023/12/31)
Japanese 206.2 KB
2023-11-10 09:05
Regulatory News Service
確認書
Japanese 8.6 KB
2023-11-10 09:03
Quarterly Report
四半期報告書-第9期第1四半期(2023/07/01-2023/09/30)
Japanese 183.3 KB
2023-09-29 08:04
Post-Annual General Meeting Information
臨時報告書
Japanese 26.0 KB

Automate Your Workflow. Get a real-time feed of all SUSMED, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for SUSMED, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Isofol Medical Logo
Developing a drug to enhance chemotherapy efficacy for solid tumors like colorectal cancer.
Sweden ISOFOL
B2B platform for Ukraine-Korea trade, investment, and post-war reconstruction.
South Korea 052770
IVISIONWORKS CO.,LTD. Logo
Accelerates social impact startups & develops digital therapeutics for cognitive rehabilitation.
South Korea 469750
A diversified, Asia-focused conglomerate with businesses in property, retail, auto, and more.
Bermuda N/A
The world's largest uranium producer, managing the front-end of the global nuclear fuel cycle.
Kazakhstan N/A
KAINOS MEDICINE, INC. Logo
Develops small molecule drugs for neurodegenerative diseases, cancers, and infectious diseases.
South Korea 284620
Kanamoto Co., Ltd. Logo
Global provider of rental construction equipment, also selling used machinery and steel products.
Japan 9678
Keihan Holdings Co.,Ltd. Logo
A conglomerate integrating transport, real estate, and retail for regional development.
Japan 9045
KNT-CT Holdings Co.,Ltd. Logo
A travel holding company offering themed tours and corporate travel solutions to boost Japan tourism.
Japan 9726
KoBioLabs, Inc. Logo
Develops AI-driven microbiome therapeutics for immune, metabolic, and brain disorders.
South Korea 348150

Talk to a Data Expert

Have a question? We'll get back to you promptly.